<DOC>
	<DOCNO>NCT00324012</DOCNO>
	<brief_summary>The trial phase II trial adrenocortical carcinoma ( ACC ) , rare malignancy poor prognosis . It provide result lead establishment effect include drug . The regimen consist cisplatin plus taxotere . Over period 1-2 year national trial include 19-36 patient advanced ACC different centre Denmark . Patients respond first line treatment switch alternative regimen . The primary objective trial investigate response rate . Secondary endpoint survival , time progression , best overall response rate duration response .</brief_summary>
	<brief_title>Trial With Taxotere Cisplatin Non-operable Adrenocortical Carcinoma</brief_title>
	<detailed_description>Treatment every three week , evaluation 2 cycle , CTC criterias use toxicity evaluation</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm diagnosis adrenocortical carcinoma Locally advance metastatic disease amenable radical surgery resection ( Stage IIIIV ) Radiologically measurable disease ECOG performance status 02 Life expectancy &gt; 3 month Age ≥18 year Adequate bone marrow reserve ( neutrophils &gt; 1500/mm3 platelet &gt; 100,000/mm3 ) Effective contraception premenopausal female male patient Patient 's write informed consent Ability comply protocol procedure ( include availability followup visit ) Previous palliative surgery , radiotherapy radiofrequency ablation acceptable long radiologically monitorable disease verifiable afterwards . History prior malignancy , except cure nonmelanoma skin cancer , curatively situ cervical carcinoma , cancer treat evidence disease least five year . Previous cytotoxic chemotherapy adrenocortical carcinoma Renal insufficiency ( serum creatinine ≥2 mg/dl creatinine clearance ≤ 60 ml/min ) Hepatic insufficiency ( serum bilirubin ≥2 x institutional upper limit normal range and/or serum transaminases ≥ 3 x institutional upper limit normal range ; exception : patient mitotane , transaminase level 5 x institutional upper limit normal range acceptable ) Pregnancy breast feed Known hypersensitivity drug include treatment protocol Presence active infection Any severe clinical condition judgment local investigator would place patient undue risk interfere study completion Current treatment experimental drug and/or previous participation clinical trial experimental agent adrenocortical carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Adrenocortical Carcinoma</keyword>
	<keyword>cisplatin</keyword>
	<keyword>taxotere</keyword>
</DOC>